


03-01-04  
FEB 27 2004  
PATENT & TRADEMARK OFFICE

Express Mail No. EV333998070US

<b>INFORMATION DISCLOSURE STATEMENT</b>    Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	TEIK-006
	First Named Inventor	SHUDO, JUTARO
	Application Number	10/675,789
	Confirmation No.	2237
	Filing Date	September 29, 2003
	Group Art Unit	1615
	Examiner Name	Unassigned
	Title:	"TOPICAL PATCH PREPARATION KIT CONTAINING A DELAYED-TYPE HYPERSENSITIVITY INDUCER"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. TEIK-006 may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: February 27, 2004

By:   
Bret E. Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/675,789
		Filing Date	September 29, 2003
		First Named Inventor	SHUDO, JUTARO
		Group Art Unit	1615
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	TEIK-006	

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		STRICKER et al. "Dendritic cells and dinitrochlorobenzene (DNCB): A new treatment approach to AIDS" <i>Immunol Letter</i> (1991) 29:191-196	
		STRICKER et al. "Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection" <i>Immunol Letters</i> , (1993) 36:1-6	
		STRICKER et al. "Topical dinitrochlorobenzene in HIV disease" <i>J. Am. Acad Dermatol</i> (1993) 28:796-797	
		STRICKER et al. "Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene (DNCB). <i>J. Am. Acad Dermatol</i> (1994) 31:462-466	
		STRICKER et al. "Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene (DNCB). <i>J. Acad Dermatol.</i> (1995) 33:608-611	
		STRICKER AND GOLDBERG "Safety of topical dinitrochlorobenzene Lancet" (1995) Vol. 346 pp. 1293	
		STRICKER et al. "Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease" <i>Res Virol</i> (1997) 148:343-348	
		TRAUB et al. "Topical immune modulation with dinitrochlorobenzene (DNCB) in HIV disease: A controlled trial from Brazil" <i>Dermatology</i> (1997) 195:369-373	
		STRICKER et al. "Topical immune modulation (TIM): A novel approach to the immunotherapy of systemic disease" <i>Immunol Letters</i> (1997) 59:145-150	
		ORACION et al. "DNCB treatment of HIV-infected patients leads to beneficial immunologic outcomes, reduced viral load, and improved measures of quality-of-life" <i>J. Invest Dermatol.</i> (1998) 110:476	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DATE: February 27, 2004



EV333998070US

THE EXPRESS MAIL NUMBER OF THE DAY IS: EV333998070US

The person taking the Express Mail to the Post Office is: Stuart McLeish

**EXPRESS MAIL CERTIFICATION**

Date of Deposit: **02/27/2004** I hereby certify that the below-listed papers or fees were inserted into a package addressed to: Commissioner for Patents, PO BOX 1450, Alexandria, Virginia 22313-1450 and was deposited by me with the United States Postal Service "Express Mail Post Office Addressee" service under 37 C.F.R. § 1.10 on the date indicated above.

Signature

Date

2/27/04

Atty. Docket No.	Serial Number	Description	Atty.	Fee
VENT-002	10/371,206	Transmittal, Fee Transmittal <i>in duplicate</i> , Preliminary Amendment	CML	
TEIK-006	10/675,789	IDS, SB08A, Copies of (10) Cited References	BEF	
SKEL-001CIP	10/109,994	PTOL-85B <i>in duplicate</i>	BEF	\$965
SKEL-008	10/717,171	IDS, SB08A, Copies of (4) Cited References	BEF	
THUR-001	09/582,964	IDS, SB08A, Copy of EP Communication dated 02/13/04, Copies of (2) Cited References	BEF	
AGIL-194	10/037,757	Transmittal, Restriction Requirement	BEF	
*CONN-001	09/780,752	PTOL-85B <i>in duplicate</i>	PAB	\$1,630